Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HRS5580 injection plus palonosetron for prevention of postoperative nausea and vomiting
CTR20262648Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fosrolapitant, palonosetron in postoperative nausea and vomiting (PONV), sponsored by Fujian Shengdi Pharmaceuticals. Started Aug 2026; status: active.
02
Drugs
fosrolapitantpalonosetron
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on CTR20262648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262648.